Aurora Cannabis
ACBAurora Cannabis Inc. (TSX: ACB, NASDAQ: ACB) is a Canadian licensed producer operating in the biotech and cannabis sectors. The company’s primary business is the production and distribution of cannabis products for both the medical and recreational markets. Its product portfolio includes dried cannabis flower, cannabis oils, and a range of ingestible products such as edibles and capsules. Aurora conducts its operations from large-scale production facilities in Canada and distributes its products domestically and internationally to markets where permissible by law. Within the medical cannabis segment, Aurora supplies products to patients and conducts research into therapeutic applications. The company has engaged in clinical studies and research partnerships exploring the potential role of cannabinoids in areas such as chronic pain, anxiety, and epilepsy. This research is part of its focus on developing standardized, quality-controlled medical cannabis products for specific patient populations and symptom management. As a publicly traded entity, Aurora Cannabis is subject to the regulatory frameworks of Health Canada and the securities regulations applicable in Canada and the United States. The company’s activities and strategic direction are influenced by the evolving legal landscape for cannabis in its core markets and the jurisdictions into which it exports. Its operations encompass cultivation, product innovation, wholesale distribution, and direct-to-consumer sales through its medical platform and recreational retail partners.
ACB · Stock Price
Historical price data
About
Aurora Cannabis Inc. (TSX: ACB, NASDAQ: ACB) is a Canadian licensed producer operating in the biotech and cannabis sectors. The company’s primary business is the production and distribution of cannabis products for both the medical and recreational markets. Its product portfolio includes dried cannabis flower, cannabis oils, and a range of ingestible products such as edibles and capsules. Aurora conducts its operations from large-scale production facilities in Canada and distributes its products domestically and internationally to markets where permissible by law. Within the medical cannabis segment, Aurora supplies products to patients and conducts research into therapeutic applications. The company has engaged in clinical studies and research partnerships exploring the potential role of cannabinoids in areas such as chronic pain, anxiety, and epilepsy. This research is part of its focus on developing standardized, quality-controlled medical cannabis products for specific patient populations and symptom management. As a publicly traded entity, Aurora Cannabis is subject to the regulatory frameworks of Health Canada and the securities regulations applicable in Canada and the United States. The company’s activities and strategic direction are influenced by the evolving legal landscape for cannabis in its core markets and the jurisdictions into which it exports. Its operations encompass cultivation, product innovation, wholesale distribution, and direct-to-consumer sales through its medical platform and recreational retail partners.